Information Provided By:
Fly News Breaks for July 13, 2015
NVCN, EW
Jul 13, 2015 | 07:48 EDT
Canaccord said they continue to like both Edwards Lifesciences (EW) and Neovasc (NVCN) in the transcatheter mitral valve replacement, or TMVR, space. The firm sees long term growth potential in the TMVR space and upside earnings and revenue potential in Edwards due to its leverage there and its acquisition of privately held CardiAQ. The firm said the removal of CardiAQ as a competitor should be positive for Neovasc and has a Buy rating on both stocks.